Boston Scientific Thursday's IBD Stock Of The Day as the medtech trades just below all-time highs it hit late last month.

Wix.com is the IBD Stock Of The Day amid the website builder's 77% share gain in 2024. Strong institutional support is a ...

Shale oil play Vista Energy has soared 81% this year and the energy stock is in a buy zone from a base. Why I Just Bought ...

Nvidia is IBD Stock Of The Day as the AI chipmaker rises above its 50-day moving average and a downward-sloping trendline.

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Spyre Therapeutics (SYRE – Research Report), with a ...

Piper Sandler analyst Christopher Raymond raised the firm’s price target on AbbVie (ABBV) to $220 from $212 and keeps an Overweight rating on ...

Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...

Teva's R&D chief, Eric Hughes, didn't hold back, calling the results beyond expectations, while Sanofi's head of R&D, Houman Ashrafian, described the drug as a frontier in treating IBD.

Sanofi stock rose nearly 7% ... Both UC and CD indications are primary forms of IBD, marked by chronic inflammation in the gastrointestinal tract. In recent years, there has been a surge in ...

Sanofi stock rose nearly 7%. Year to date, the stock fell 1.6% against the industry’s 5.3% growth. Zacks Investment Research Image Source: Zacks Investment Research Shares of Teva jumped 26% ...